Astellas/Pfizer’s Xtandi and Johnson & Johnson’s Erleada are both now approved for non-metastatic castration-resistant prostate cancer in Europe, while Xtandi benefits from physician familiarity, Erleada has shown greater metastasis-free survival.

Valneva’s 2019 guidance has been boosted by the US Army’s Ixiaro vaccine order, as other products flourish in the pipeline.

Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.

Six months after selling its critical care business to refocus on rare diseases and oncology, EUSA Pharma has made its first move into those markets by licensing a Janssen product for a rare blood disorder.

Mersana Therapeutics has discontinued its lead candidate because of the competitive landscape surrounding HER2-targeted therapies, and will refocus on its only other clinical program, the NaPi2b-targetting ADC XMT-1536 for ovarian cancer and NSCLC.